Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308586 | 0.92 | DRD2 (0.64) | DRD2DRD4DRD3TRIM24TRIM33 | |
| SCHEMBL16610749 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL16610748 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3POLBALDH1A1 | |
| SCHEMBL28035388 | 0.70 | NPC1 (0.40) | DRD2DRD4DRD3POLBGLA | |
| SCHEMBL3188494 | 0.69 | TRIM24 (0.44) | DRD2DRD4DRD3TRIM24TRIM33 | |
| SCHEMBL30558157 | 0.68 | KDM5A (0.39) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL29287218 | 0.68 | SLC18A3 (0.39) | ALDH1A1SLC18A3GAA | |
| SCHEMBL8139572 | 0.68 | SLC18A3 (0.39) | ALDH1A1SLC18A3GAA | |
| SCHEMBL15797759 | 0.68 | ALDH1A1 (0.40) | ALDH1A1SLC18A3 | |
| SCHEMBL24915363 | 0.68 | DRD2 (0.41) | DRD2DRD4DRD3TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104507940-B | Heterocyclic compounds | 武田药品工业株式会社 | 2017-01-25 | — | — | CN | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| CN-104507940-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2015-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DRD2 4477/4885DRD4 4802/4885DRD3 4255/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DRD2 4477/4885DRD4 4802/4885DRD3 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.